Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment
Osteoporosis International — Tominaga A, Wada K, Okazaki K, et al. | January 24, 2022
Bone resorption is suppressed and bone formation is stimulated in correlation with receiving an anti-sclerostin antibody, romosozumab. Researchers herein examined if the duration of previous treatment with teriparatide, denosumab, or oral bisphosphonates influences the effectiveness of 12 months of romosozumab treatment.
Subcutaneous injections of romosozumab (210 mg) were administered every 4 weeks to 259 osteoporosis patients during 2019 and 2020.
Depending on the type and duration of previous treatment before starting romosozumab, division of the patients was done into seven groups: non-previous treatment group, change from teriparatide used for 1 year or less/more than 1 year, change from denosumab used for 1 year or less/more than 1 year, and change from oral bisphosphonates used for 1 year or less/more than 1 year. Per findings, the effectiveness of romosozumab appeared to be influenced by the duration of the previous treatment.
There was attenuation in the effect of romosozumab in correlation with using denosumab and oral bisphosphonate for more than 1 year.